Immunovia
Immunovia AB (publ) is a Swedish diagnostics company that developed and commercially launched the PancreaSure blood test, a five-biomarker ELISA assay for early detection of pancreatic cancer at stages 1 and 2, served via US healthcare providers to high-risk patients identified by family history or genetic predisposition.
- Company typePublic
- Founded2015
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Immunovia does
Immunovia AB (publ) is a Swedish diagnostics company founded in 2015 in Lund, based on protein biomarker research from Lund University, that develops and commercializes the PancreaSure blood test for early detection of pancreatic ductal adenocarcinoma (PDAC) at stages 1 and 2. The test is positioned for the 1.8 million individuals in the US estimated to be at high risk due to family history or hereditary genetic mutations such as BRCA1/2, Lynch Syndrome, and Peutz-Jeghers, where current standard surveillance relies on invasive endoscopic ultrasound or MRI.
PancreaSure is a laboratory-developed test measuring five protein biomarkers via an ELISA (Enzyme-Linked Immunosorbent Assay) platform processed at Immunovia's CLIA- and CAP-certified laboratory in Durham, North Carolina. The assay was validated through three clinical studies: CLARITI (78% sensitivity and 94% specificity in 1,066 samples), VERIFI (77% detection of stage I/II cancer), and AFFIRM (88% sensitivity and 98% specificity in average-risk populations), with results published in the Journal of Clinical Oncology: Oncology Advances and presented at Digestive Disease Week 2025. In 2023, Immunovia discontinued its proprietary IMMray platform in favor of a commercially available ELISA platform to reduce per-test cost and accelerate turnaround to 7-10 business days. A subsequent proteomics study using Olink explored nearly 3,000 proteins and identified more than a dozen candidates capable of detecting stage I/II PDAC, suggesting a pipeline for an upgraded assay.
Immunovia's revenue model is transactional: physicians order PancreaSure through a HIPAA-compliant provider portal, blood samples are shipped to the Durham lab, and Immunovia bills insurance or patients directly at $200 or less for qualifying patients via a federal-poverty-guideline-based financial assistance program, or $750 discounted cash pay. The company is pursuing Medicare Local Coverage Determination (LCD) to expand payer access. Q1 2026 net sales were 374 KSEK with an operating loss of 18.4 MSEK, reflecting the early stage of US commercialization following the Q3 2025 launch. Immunovia AB is publicly listed on Nasdaq Stockholm (IMMNOV; ISIN SE0006091997) and operates the commercial business through its wholly-owned US subsidiary Immunovia Inc.
Immunovia firmographics
Firmographics- Name
- Immunovia
- Legal name
- Immunovia AB (publ)
- Website
- https://immunovia.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immunovia AB (publ) is a Swedish diagnostics company that developed and commercially launched the PancreaSure blood test, a five-biomarker ELISA assay for early detection of pancreatic cancer at stages 1 and 2, served via US healthcare providers to high-risk patients identified by family history or genetic predisposition.
- Ownership category
- akta.pro rank
Immunovia industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Immunovia is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Immunovia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- PancreaSure Test Sales: Revenue generated from selling the PancreaSure blood test to patients and healthcare providers. The test is ordered by clinicians and samples are processed in Immunovia's CLIA and CAP certified laboratory in Durham, NC. Revenue comes from insurance reimbursement and direct patient payment.
- Insurance Reimbursement: Revenue from insurance companies and Medicare for covered PancreaSure tests. The company is pursuing Medicare coverage through a Local Coverage Determination (LCD) application.
- Royalties: Q1 2026 net sales of 374 KSEK included royalties and revenues from PancreaSure tests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Standard insurance billing with financial assistance |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Immunovia product offering
Product offeringCore offering
Immunovia develops and commercializes PancreaSure, a blood-based biomarker test that detects pancreatic ductal adenocarcinoma (PDAC) at Stage 1 and 2 by measuring five protein biomarkers in patient blood samples. The test is ordered by healthcare providers (gastroenterologists, oncologists, and primary care physicians) for high-risk individuals with family history or genetic predispositions to pancreatic cancer, with samples processed at the company's CAP and CLIA certified laboratory in Durham, North Carolina.
Product overview
Immunovia is a single-product diagnostics company focused on early detection of pancreatic cancer. The company's primary offering is the PancreaSure blood test, a laboratory-developed test that analyzes five biomarkers to detect pancreatic ductal adenocarcinoma (PDAC) at early stages (1 and 2). The company previously offered the IMMray PanCan-d test but discontinued it in Q3 2023 to focus resources on its next-generation PancreaSure test. Immunovia operates through its CAP and CLIA-certified laboratory in Durham, NC, and sells directly to healthcare providers and patients in the United States.
Differentiator
Problem solved
Functional benefit
Brands
- PancreaSure: Blood-based biomarker test for early detection of pancreatic cancer at stage 1 and 2 with 78% sensitivity and 94% specificity. CLIA and CAP certified laboratory test measuring five biomarkers.
- IMMray
Products and services
- PancreaSure PancreaSure is a laboratory-developed blood test that measures five different biomarkers to detect pancreatic ductal adenocarcinoma (PDAC) at Stage 1 or 2, when treatment is more likely to be effective. It is intended for people at elevated risk for pancreatic cancer due to family history or genetic mutations (BRCA1/2, PALB2, Lynch Syndrome, FAP, STK11/LKB1, CDKN2A, PRSS1, ATM, TP53). Samples are processed at Immunovia's CAP and CLIA certified laboratory in Durham, NC, with results delivered within 7-10 business days.
Quantifiable outcome
- 78% sensitivity for Stage I and II pancreatic cancer detection in CLARITI study of 1,066 blood samples
- +5 more outcomes
Companies that use Immunovia
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Immunovia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Immunovia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Proteomedix AGcoreIn November 2022, Immunovia entered into an agreement with Swiss company Proteomedix AG to access their extensive experience in developing protein-based assays to detect cancer. This partnership supported the development of the next-generation test for early detection of pancreatic cancer.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Immunovia competitors and assessment
Company assessmentDirect peers
- Myriad Genetics: Myriad is a leading US molecular diagnostics company with oncology and hereditary cancer tests. Several Immunovia executives and board members (CEO Borcherding, director Riggsbee) previously led commercial operations at Myriad, and both compete in cancer risk assessment and detection.
- Exact Sciences: Exact Sciences markets Cologuard, a non-invasive blood-based screening test for colorectal cancer, and is expanding its multi-cancer early detection pipeline. It is the most direct commercial analog to Immunovia's blood-based cancer screening model.
- Guardant Health: Guardant Health is a US oncology diagnostics company with blood-based liquid biopsy tests for cancer detection and monitoring. Like Immunovia, it sells through clinicians and pursues Medicare reimbursement for novel assays.
- Natera: Natera develops cell-free DNA-based tests for oncology and reproductive health. Its Signatera MRD test competes in the hospital-channel blood-based cancer diagnostics market that Immunovia is targeting in the US.
Emerging players
- GRAIL: GRAIL is developing the Galleri multi-cancer early detection test using blood-based methylation sequencing. While broader in scope, GRAIL competes for the same early-detection blood-test thesis and physician/patient mindshare as PancreaSure.
- VolitionRx: VolitionRx is developing blood-based biomarker tests (Nu.Q) for cancer detection, including colorectal and other cancers. It is a smaller diagnostics peer with a similar blood-based biomarker strategy and clinical validation pathway.
- Freenome: Freenome is developing multiomics blood-based screening tests for early cancer detection. It overlaps with Immunovia's premise of non-invasive screening using blood samples, particularly in early-stage cancer detection.
- Interpace Biosciences: Interpace Biosciences provides molecular diagnostics focused on gastroenterology and pancreatic cancer risk assessment (e.g., PancraGEN). It addresses the same patient population using oncology biomarker testing through a CLIA-certified lab.
Broad incumbents
- Laboratory Corporation of America (LabCorp): LabCorp is a major US clinical reference laboratory that performs a wide range of specialty diagnostics. Director Bryan Riggsbee is a former senior LabCorp financial leader. LabCorp could partner with or compete against Immunovia's PDAC testing.
- Quest Diagnostics: Quest is a leading US clinical laboratory offering oncology and genetic testing services. Its broad specialty menu and physician relationships make it a natural incumbent peer for blood-based cancer screening tests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Immunovia social profiles
Digital presenceImmunovia compliance and trust
Trust signalCompliance3 records
Immunovia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunovia leadership team
Management profileNumber of profiles
Profiles11 records
Immunovia subsidiaries and ownership
Company hierarchySubsidiaries1 record
Immunovia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunovia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunovia
What does Immunovia do?
Immunovia develops and commercializes PancreaSure, a blood-based biomarker test that detects pancreatic ductal adenocarcinoma (PDAC) at Stage 1 and 2 by measuring five protein biomarkers in patient blood samples. The test is ordered by healthcare providers (gastroenterologists, oncologists, and primary care physicians) for high-risk individuals with family history or genetic predispositions to pancreatic cancer, with samples processed at the company's CAP and CLIA certified laboratory in Durham, North Carolina.
Is Immunovia a public or private company?
Immunovia is a public company. It is classified as public and is currently operating.
When was Immunovia founded?
Immunovia was founded in 2015. It employs 11 to 50 people.
Where is Immunovia based?
Immunovia is headquartered in Lund, Sweden, in the Europe region.
How does Immunovia make money?
Three revenue lines are on record. PancreaSure Test Sales are the primary driver. The others are insurance Reimbursement and royalties.
Who are Immunovia's main competitors?
Direct peers on record are Myriad Genetics, Exact Sciences, Guardant Health and Natera. Emerging players are GRAIL, VolitionRx, Freenome and Interpace Biosciences. Broad incumbents are Laboratory Corporation of America (LabCorp) and Quest Diagnostics.
Does Immunovia have an API?
No public API is recorded for Immunovia.
What industry is Immunovia in?
Immunovia's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 621511 and its SIC code is 8071.